The primary purpose of this study is to investigate if treatment with Ixazomib in multiple
myeloma (MM) can strengthen the bones, thus making it resilient to future fractures. Ixazomib
will be given at a time point when the disease is in a stable phase, decreasing the
likelihood that the potential bone anabolic effect will be abrogated by catabolic effect of
active MM. In order to be included in the study, the patient must have treatment demanding
MM, and the disease must have been brought into at least partial remission with chemotherapy
before inclusion. Moreover, the patient must have pathological bone structure on low dose CT
due to the pre-existing disease.